Javascript must be enabled to continue!
Description of the international consortium for prostate cancer genetics, and failure to replicate linkage of hereditary prostate cancer to 20q13
View through CrossRef
AbstractThe International Consortium for Prostate Cancer Genetics (ICPCG) is an international collaborative effort to pool pedigrees with hereditary prostate cancer (PC) in order to replicate linkage findings for PC. A strength of the ICPCG is the large number of well‐characterized pedigrees, allowing linkage analyses within large subsets. Given the heterogeneity and complexity of PC, the historical difficulties of synthesizing different studies reporting positive and negative linkage replication, and the use of different statistical analysis methods and different stratification criteria, the ICPCG provides a valuable resource to evaluate linkage for hereditary PC. To date, linkage of chromosome 20 (HPC20) to hereditary PC has been one of the strongest linkage signals, yet the efforts to replicate this linkage have been limited. This paper reports a linkage analysis of chromosome 20 markers for 1,234 pedigrees with multiple cases of PC ascertained through the ICPCG, and represents the most thorough attempt to confirm or refute linkage to chromosome 20. From the original 158 Mayo pedigrees in which linkage was detected, the maximum heterogeneity LOD (HLOD) score, under a recessive model, was 2.78. In contrast, for the 1,076 pedigrees not included in the original study, the maximum HLOD score (recessive model) was 0.06. Although, a few small linkage signals for chromosome 20 were found in various strata of this pooled analysis, this large study failed to replicate linkage to HPC20. This study illustrates the value of the ICPCG family collection to evaluate reported linkage signals and suggests that the HPC20 region does not make a major contribution to PC susceptibility. © 2004 Wiley‐Liss, Inc.
Title: Description of the international consortium for prostate cancer genetics, and failure to replicate linkage of hereditary prostate cancer to 20q13
Description:
AbstractThe International Consortium for Prostate Cancer Genetics (ICPCG) is an international collaborative effort to pool pedigrees with hereditary prostate cancer (PC) in order to replicate linkage findings for PC.
A strength of the ICPCG is the large number of well‐characterized pedigrees, allowing linkage analyses within large subsets.
Given the heterogeneity and complexity of PC, the historical difficulties of synthesizing different studies reporting positive and negative linkage replication, and the use of different statistical analysis methods and different stratification criteria, the ICPCG provides a valuable resource to evaluate linkage for hereditary PC.
To date, linkage of chromosome 20 (HPC20) to hereditary PC has been one of the strongest linkage signals, yet the efforts to replicate this linkage have been limited.
This paper reports a linkage analysis of chromosome 20 markers for 1,234 pedigrees with multiple cases of PC ascertained through the ICPCG, and represents the most thorough attempt to confirm or refute linkage to chromosome 20.
From the original 158 Mayo pedigrees in which linkage was detected, the maximum heterogeneity LOD (HLOD) score, under a recessive model, was 2.
78.
In contrast, for the 1,076 pedigrees not included in the original study, the maximum HLOD score (recessive model) was 0.
06.
Although, a few small linkage signals for chromosome 20 were found in various strata of this pooled analysis, this large study failed to replicate linkage to HPC20.
This study illustrates the value of the ICPCG family collection to evaluate reported linkage signals and suggests that the HPC20 region does not make a major contribution to PC susceptibility.
© 2004 Wiley‐Liss, Inc.
Related Results
Frequency of Common Chromosomal Abnormalities in Patients with Idiopathic Acquired Aplastic Anemia
Frequency of Common Chromosomal Abnormalities in Patients with Idiopathic Acquired Aplastic Anemia
Objective: To determine the frequency of common chromosomal aberrations in local population idiopathic determine the frequency of common chromosomal aberrations in local population...
Abstract 4602: Clinicopathological and genetic features of prostate cancer in Algerian patients: First report
Abstract 4602: Clinicopathological and genetic features of prostate cancer in Algerian patients: First report
Abstract
Background: Prostate cancer is the second most frequent malignancy (after lung cancer) in men worldwide. It is the third most common cancer in men in Algeri...
Abstract 1341: Identification of significant linkage evidence for lethal prostate cancer on chromosome arm 11p15.
Abstract 1341: Identification of significant linkage evidence for lethal prostate cancer on chromosome arm 11p15.
Abstract
We performed genome wide linkage analysis in a set of high-risk prostate cancer pedigrees, each with 3 or more sampled cases whose death certificate indicat...
Abstract 5758: Deletions of olfactomedin 4 gene is associated with progression of prostate cancer
Abstract 5758: Deletions of olfactomedin 4 gene is associated with progression of prostate cancer
Abstract
The human olfactomedin 4 gene (OLFM4) encodes an olfactomedin-related glycoprotein, which our group first cloned and characterized in myeloid cells and mapp...
Abstract 1568: The role of CCL2 CCL17 CCL22-CCR4 axis in prostate cancer metastasis
Abstract 1568: The role of CCL2 CCL17 CCL22-CCR4 axis in prostate cancer metastasis
Abstract
BACKGROUND: Multiple steps and factors are involved in prostate carcinogenesis and tumor progression. The early studies have found that tumor-associated mac...
Grade Group 1 Prostate Cancer Outcome by Biopsy Grade and Risk Group
Grade Group 1 Prostate Cancer Outcome by Biopsy Grade and Risk Group
ImportanceAdvocates for removing the cancer label from grade group 1 (GG1) prostate cancer detected on biopsy primarily base their argument on the observation that when only GG1 is...
Study on Early Prostate Cancer Antigen (EPCA) and existent risk factors of prostate cancer, Sudan: A case-control study
Study on Early Prostate Cancer Antigen (EPCA) and existent risk factors of prostate cancer, Sudan: A case-control study
Background: Early prostate cancer antigen (EPCA), a nuclear matrix protein, has recently been recommended as a hopeful biomarker for early prostate carcinogenesis. Objectives: To e...
Abstract B050: STATE OF PROSTATE CANCER IN CAMEROON in 2025
Abstract B050: STATE OF PROSTATE CANCER IN CAMEROON in 2025
Abstract
• A. INTRODUCTION Cameroon is experiencing an increase in the prevalence of chronic non-communicable diseases, ...

